ArticleSeminars in ophthalmology2022
Long term follow-up of visual acuity and incidence of subretinal neovascularization in Mactel Type 2 in 82 Eyes.
Article in Seminars in ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Macular telangiectasia type 2: An update.The Journal of international medical research · 2026Review
- Ethnic comparison of MacTel over 5 years follow up.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Observational
- Macular Telangiectasia Type 2: The Role of Optical Coherence Tomography and Management Options.Journal of clinical medicine · 2026Review
- Results from a Phase I Extension Study of Ciliary Neurotrophic Factor in Patients with Macular Telangiectasia Type 2.Ophthalmology science · 2026Article
- Article
- Macular Telangiectasia Type 2: Long-Term Disease Progression and Management of Complications.Turkish journal of ophthalmology · 2025Article
- Longitudinal anatomical and visual outcome of macular telangiectasia type 2 in Asian patients.Scientific reports · 2023Article
- Early Optical Coherence Tomography Biomarkers for Selected Retinal Diseases-A Review.Diagnostics (Basel, Switzerland) · 2023Review
- Intravitreal Bevacizumab for Choroidal Neovascular Membrane in Macular Telangiectasia Type 2.Cureus · 2023Article
- Characteristics of retinal pigment clumps in Type 2 macular telangiectasia (MacTel).Eye (London, England) · 2023Article
- Macular Telangiectasia Type 2: A Comprehensive Review.Clinical ophthalmology (Auckland, N.Z.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
Abstract
purpose: To evaluate the long-term natural course of macular telangiectasia Type 2, correlation with visual acuity and the incidence of Choroidal Neovascularisation (CNV) in Indian eyes. MATERIAL AND
methods: A Retrospective analysis of Patients with MacTel Type 2 was done over a period of 12 years with all patients having a minimum of 3 years follow up. The demographic details and ocular characteristics including best-corrected visual acuity (BCVA), fundus photography, fluorescein angiography, and optical coherence tomography images were studied in both proliferative and non-proliferative MacTel. Mixed models were used to estimate progression rates and a Kaplan Meier estimation of BCVA was plotted.
results: Eighty-two eyes of 47 patients were studied over a period of mean duration of 4.5 years (range: 3 years-8.5 years). There was no difference in the demographic characteristics between the non-proliferative MacTel and proliferative MacTel groups. There were no significant risk factors observed for progression. However, patients with retinal greying had significant risk reduction for a BCVA decline. The mean logMAR BCVA decreased from 0.25 ± 0.25 at baseline to 0.46 ± 0.42 by 4 years. Twenty-eight percent of the patients maintained their vision 8 years from baseline and were unlikely to progress. The incidence of CNV was 10.6% and the mean duration for the development of CNV was 2.36 years from baseline. Seventy-Three percent (11 of 15) patients with CNV had a BCVA of <20/40.
conclusion: In patients of MacTel, the maximum vision loss occurred at the fourth year and then stabilized. The major cause of poor vision observed was CNV (active in 10.98% and scarred in 7.32%), foveal atrophy (10.98%) and central pigmented plaques (3.66%). The incidence of sight-threatening complication of CNV (10.6%) is likely to occur only in a minority of eyes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.